AlphAIAlphAI — Financial news for AI agents
seekingalpha.comOCT 281 min read$GMAB

Genmab stock rises on Phase 3 cancer trial data (GMAB:NASDAQ)

Genmab's stock rose 15% after announcing Phase 3 trial data showed its bispecific antibody therapy, petosemtamab, with Merck's Keytruda reduced mortality risk by 50% in certain head and neck cancer patients.

Original reporting
seekingalpha.com
Published Oct 28, 2026, 2:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 2:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$GMAB
Bullish
high confidence
Mentioned
$GMAB
Relevance
9/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$GMABBullishHigh
01

Why it matters

The data represents a significant efficacy signal, prompting a sharp stock rally.

02

Market read

First‑report of pivotal trial data; likely to influence Genmab and related oncology stocks.

03

What to watch

Potential safety signals or trial enrollment challenges could temper upside.

Relevance 9/10Novelty 9/10Timing: today

Background

Genmab announced Phase 3 data for its bispecific antibody combined with Merck's Keytruda.

Company-level read

Ticker impact

$GMABBullishHigh confidence
Context

Phase 3 trial shows petosemtamab reduces mortality risk by 50% in head and neck cancer patients, driving a 15% stock rise.

Expected impact

upward pressure as investors price in the mortality risk reduction.

Evidence & confidence

Phase 3 results are material for a biotech and have already moved the stock 15%.

Market effects

Sector

May boost sentiment for oncology biotech peers.

Regional

Limited to US and European biotech markets.

Global

Modest, primarily affects biotech investors worldwide.

Counterpoint

What could challenge this read

Skeptics may question long‑term survival benefit and regulatory path.

Key entities

  • company
    Genmab

    Danish biotech developing petosemtamab.

  • company
    Merck

    Provider of Keytruda, partner in the trial.

Read at source← All news

StoryGenmab reports 50% mortality cut in Phase 3 head‑and‑neck cancer trial

Also covered by

1 outlet

Related articles

OCT 28
$GMABHighAI 9/10

Genmab reports 50% lower death risk in Phase 3 trial

Genmab reported that its petosemtamab combination reduced the risk of death by 50% in a Phase 3 head-and-neck cancer trial, meeting both primary endpoints. The study involved 699 patients. Genmab's shares rose 15.22% to $51.47 on Wednesday. The company plans to discuss results with global regulators.

mugglehead.com2 min
OCT 28
$GMABHigh

Genmab A/S: Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer

Genmab (GMAB) reported positive Phase 3 trial results for petosemtamab in combination with pembrolizumab, showing a 50% reduction in death risk for PD-L1+ head and neck cancer patients. The trial met both primary endpoints, and the company plans to engage regulators and present full results. Petosemtamab is also being evaluated in other Phase 3 trials for different cancers.

finanznachrichten.de2 min
OCT 28
$GMABHighAI 9/10

Why is Genmab stock surging today?

Genmab's stock rose 16.8% after its Phase 3 LiGeR-HN1 trial showed a 50% reduction in death risk for a combination treatment. Analysts upgraded the stock, with JPMorgan raising its price target to DKK 3,500 and TD Cowen to $52.00. The trial results were well-received, with no new safety concerns.

investing.com2 min
OCT 28
$GMABHigh

Genmab’s petosemtamab trial cuts death risk by 50% in cancer

Genmab A/S (GMAB) reported that its Phase 3 trial for petosemtamab met primary endpoints, reducing death risk by 50% in head and neck cancer patients. The combination therapy showed significant improvements in overall survival and response rates, with a hazard ratio of 0.50 and an objective response rate odds ratio of 3.17. The company plans regulatory submissions and further trial evaluations. Head and neck squamous cell carcinoma is the seventh most common cancer globally.

investing.com2 min